• Electrochemiluminescent materials with 100-fold higher analytical signal intensity compared to the gold standard, [Ru(bpy)3]2+;
  • Multiplexed detection of pathogens by tuning the emission wavelength and redox potential of the luminophores;
  • Exquisitely selective identification of pathogens using recombinant antibodies – this allows the optimum antibiotic to be rapidly administered;
  • Creation of innovative sample-to-answer devices for sepsis associated biomarker and whole bacteria detection;
  • ECLectic will set an “in depth and multidisciplinary” doctoral research program for establish a new generation of scientist with a multidisciplinary approach in the field of biosensors.


  • Providing that we meet the technological benchmark goals set above, we envision that industry stakeholders will begin an accelerated development process, which will in turn lead within few years to extend the use of ECLectic diagnostics tools in public healthcare and sepsis prevention. Consequently, we envision that ECLectic will have far-reaching implications not only for the diagnostics field, but also for various life-science related sectors, thus extending state-of-the-art fundamental and applied sciences and contribute to further strengthen a scientifically competitive;
  • The novel ECL nanomaterials and protocols for the ECL generation could be technologies licensed to a large pharma diagnostic company;
  • ECLectic will set a doctoral network where DCs gain soft skills and experience both regarding academic research and business environment. This will allow to boost the economical aspect of the ECLectic and prepare European junior participants able to interact with industries and able to optimize the economic aspects of their research results.


  • The ECLectic innovations will enable early diagnosis of sepsis and the rapid administration of the optimum antibiotic by identifying the causative organism, and allow clinicians ensure that the therapy is effective;
  • The minimization of the reagents in agreement with the European Green Deal;
  • The sensing in a short time (minutes) and eventually in decentralized environment (emergency room, clinician offices or traveling sites such as airports and train stations);
  • The potential utility of this platform in developing countries where clinical laboratory infrastructures are very poor and cost constraints are relevant;
  • Training the next generation of clinically oriented analytical scientists capable of delivering innovative scientific solutions that will improve the lives of patients and drive economic prosperity.